UC San Diego Health

Bridging Clinical Foundations and Digital Innovation: Optimizing Hypertension Care in Pregnancy and Beyond

Ukachi N. Emeruwa, MD, MPH

Assistant Professor | Women's Reproductive Health Research Scholar Division of Maternal-Fetal Medicine Department of Obstetrics, Gynecology, and Reproductive Sciences University of California San Diego Health Thursday, May 15, 2025

Today's Focus

- The state of maternal health in the US
- Why hypertension matters in pregnancy
- What are hypertensive disorders of pregnancy
- Why families face gaps in care
- Innovations in maternal hypertension care
- Core elements of quality hypertension care



The state of maternal health in the US

A national crisis





U.S. Maternal Mortality Crisis

There are more pregnancy-related deaths today than 40 years ago, and the number is **rising**.

Maternal mortality ratio in the U.S. (1987-2013)



U.S. Maternal Mortality Rate Has Been Getting Worse over Time

Deaths per 100,000 live births



Notes: The maternal mortality ratio is defined by the World Health Organization as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

Data: Data for all countries except US from OECD Health Statistics 2022. Data for US from Donna L. Hoyert, <u>Maternal Mortality Rates in the</u> <u>United States</u>, 2020 (National Center for Health Statistics, Feb. 2022).

Source: Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II, "The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison," To the Point (blog), Commonwealth Fund, Dec. 1, 2022. <u>https://doi.org/10.26099/8vem-fc65</u>

Why hypertension in pregnancy matters

A maternal mortality case study



UC San Diego Health





maternal deaths attributable to **HYPERTENSIVE DISORDERS OF PREGNANCY** globally





increase in preeclampsia incidence in the United States between 1987 and 2004





increase in hypertensive disorder or pregnancy increase between 2010 and 2021

Why hypertension in pregnancy matters

- Leading cause of maternal
 morbidity and mortality
- Causes up to 15% of preterm births and contributes to nearly 20% of stillbirths
- Impacts Black and Indigenous
 patients disproportionately
- Often develops silently, during or after pregnancy
- Early recognition and continued care save lives



What are hypertensive disorders of pregnancy

Opportunities for understanding and educating

UC San Diego Health



Postpartum hypertension

A placental problem

- **RENAL**: proteinuria, edema, renal dysfunction
- **PULMONARY:** shortness of breath, pulmonary edema
- **NEURO:** headache, visual disturbances, seizures
- **HEPATIC:** right upper quadrant pain, liver dysfunction
- **Нематоlogic**: thrombocytopenia, hemolysis, hemoconcentration
- **(Cardio)vascular:** high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities, abruption



A placental problem

- **RENAL**: proteinuria, edema, renal dysfunction
- **PULMONARY:** shortness of breath, pulmonary edema
- **NEURO:** headache, visual disturbances, seizures
- **HEPATIC:** right upper quadrant pain, liver dysfunction
- **HEMATOLOGIC:** thrombocytopenia, hemolysis, hemoconcentration
- (CARDIO)VASCULAR: high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities, abruption



- **RENAL**: proteinuria, edema, renal dysfunction
- **PULMONARY:** shortness of breath, pulmonary edema
- **NEURO:** headache, visual disturbances, seizures
- **HEPATIC:** right upper quadrant pain, liver dysfunction
- **Нематоlogic**: thrombocytopenia, hemolysis, hemoconcentration
- (CARDIO)VASCULAR: high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities, abruption



- **RENAL: proteinuria**, edema, **renal** dysfunction
- **PULMONARY:** shortness of breath, pulmonary edema
- **NEURO:** headache, visual disturbances, seizures
- HEPATIC: right upper quadrant pain, liver dysfunction
- **Нематоlogic: thrombocytopenia**, <u>hemolysis</u>, hemoconcentration
- (CARDIO)VASCULAR: high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities, abruption



- **RENAL**: proteinuria, **edema**, renal dysfunction
- **PULMONARY: shortness of breath**, pulmonary edema
- **NEURO: headache**, **visual disturbances**, seizures
- **HEPATIC: right upper quadrant pain**, liver dysfunction
- **Нематоlogic**: thrombocytopenia, hemolysis, hemoconcentration
- **(Cardio)vascular:** high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities, abruption





What is preeclampsia?

Part of a spectrum of conditions of Hypertensive disorders of pregnancy (HDP):

Placental dysfunction which releases factors that <u>can affect</u> <u>almost every system in your body</u>





Diagnostic criteria for hypertensive disorders of pregnancy

Condition	Definition	>
Chronic Hypertension	SBP \geq 130 or DBP \geq 80 mmHg prior to 20 th week pregnancy	f Pregnanc
Gestational Hypertension	SBP \geq 140 or DBP \geq 90 mmHg after to 20 th week pregnancy on >2 occasions	Disorder o
Preeclampsia	Blood Pressure • SBP ≥140 or DBP ≥90 mmHg after to 20 th week pregnancy on >2 occasions • OR Single reading of SBP ≥160 or DBP ≥110 mmHg after 20 th week pregnancy AND Proteinuria • ≥300g 24hr urine collection • OR protein:creatine ratio ≥ 0.3 • OR dipstick reading of ≥2+ OR any of the following: • Platelets <100x10 ⁹ /L • Serum creatinine >1.1 mg/dL • Doubling of baseline transaminases	Gestational Age 1 2 5 4 5 5 7 0 5 10 11 12 12 1
	New onset headache unresponsive to medication without alternative diagnosis	

Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol.* 2020;135(6):e237-e260. American College of O, Gynecologists' Committee on Practice B-O. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. *Obstet Gynecol.* 2019;133(1):e26-e50.

Table 1. Definitions of hypertensive disorders of pregnancy^{12,13}



Tools to reduce HDP Risk

- **Education** of disorder, signs, and symptoms
- **SCREENING** at prenatal visits (and beyond)
- **Ркорнуцахіs** with aspirin 81 mg for the right candidate
- **TREATMENT** as soon as indicated
 - Antihypertensives: PO over 140/90, IV over 160/110
 - Magnesium sulfate for seizure prophylaxis
- **FETAL MONITORING** when any HDP is diagnosed
- **DELIVERY** when maternal (or fetal) risks outweigh fetal benefits
- **Research** into better diagnostics and treatments



Why families face gaps in care

The "Fourth Trimester" danger zone

UC San Diego Health



The rise of postpartum morbidity and mortality

Exhibit 2

Timing of U.S. Maternal and Pregnancy-Related Deaths, 2011–2015



Data: Centers for Disease Control and Prevention Pregnancy-Related Mortality Surveillance data from: Emily E. Petersen et al., "Vital Signs: Pregnancy-Related Deaths, United States, 2011–2015, and Strategies for Prevention, 13 States, 2013–2017," *Morbidity and Mortality Weekly Report* 68, no. 18 (May 10, 2019): 423–29.

Source: Roosa Tikkanen et al., Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries (Commonwealth Fund, Nov. 2020). https://doi.org/10.26099/411v-9255

Leading clinical causes of pregnancy-related mortality up to one year post-birth, U.S., 2007–2016 (%)



The rise of postpartum morbidity and mortality



Leading clinical causes of pregnancy-related mortality up to one year post-birth, U.S., 2007–2016 (%)

Hypertensive Disorders of Pregnancy (HDP)







of hypertension-related maternal deaths occur after delivery

Contributors to postpartum HDP

Πιπραιοι	s to postpar		fluid	space	capillary wedge pressure	associated complications
	Blood Chemistry	Increased number of blood cells Increased clotting factors Increased fibrinolytic activity Iron deficiency and anemia				
Changes in	Cardiovascular System	Tachycardia Increased cardiac output and heart rate Increased stroke volume				SP .
Pregnancy	Respiratory System	Displacement of diaphragm superiorly Decreased functional reserve capacity Increased the risk of apnea and dyspnea Hyperventilation				
	Gastrointestinal System	Nausea and vomiting Heart burn and acidity		N.	6	
	General Changes	Mode and behavioral changes Increased nutritional demands				

Sequestered extravascular

PREGNANCY NONPREGNANT

Central venous

pressure & pulm

Auto-infusion to

intravascular

Postpartum

hypertension and

- **RENAL**: proteinuria, **edema**, renal dysfunction
- **PULMONARY: shortness of breath**, pulmonary edema
- **NEURO: headache**, **visual disturbances**, seizures
- **HEPATIC: right upper quadrant pain**, liver dysfunction
- **Нематоlogic:** thrombocytopenia, hemolysis, hemoconcentration
- **(Cardio)vascular:** high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities



Warning signs and symptoms or *normal pregnancy*?

- **RENAL**: proteinuria, **edema**, renal dysfunction
- **PULMONARY: shortness of breath**, pulmonary edema
- **NEURO: headache**, visual disturbances, seizures
- HEPATIC: right upper quadrant pain, liver dysfunction
- **Нематоlogic**: thrombocytopenia, hemolysis, hemoconcentration
- **(CARDIO)VASCULAR:** high blood pressure, edema, hemolysis
- **FETOPLACENTAL:** fetal growth restriction, fetal heart tracing abnormalities



Increased number of blood cells

Increased clotting factors

Increased fibrinolytic activity Iron deficiency and anemia Tachycardia

Increased cardiac output and heart rate Increased stroke volume

Displacement of diaphragm superiorly

Decreased functional reserve capacity

Increased the risk of apnea and dyspnea

Hyperventilation Nausea and vomiting

Heart burn and acidity

Mode and behavioral changes

Increased nutritional demands

Blood Chemistry

Cardiovascular System

Respiratory System

Gastrointestinal System

General Changes

Changes in

Pregnancy

Contributors to postpartum HDP morbidity and mortality



Proposed paradigm shift for postpartum visits



Notes: Adapted from ACOG Committee Opinion Number 736: Optimizing postpartum care. F/U = follow-up. Source: Obstet Gynecol. 2018;131:e140-50

U.S. Maternal Mortality Crisis

U.S. Maternal Mortality Rate Has Been Getting Worse over Time

Deaths per 100,000 live births



Notes: The maternal mortality ratio is defined by the World Health Organization as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

Data: Data for all countries except US from OECD Health Statistics 2022. Data for US from Donna L. Hoyert, <u>Maternal Mortality Rates in the</u> <u>United States, 2020</u> (National Center for Health Statistics, Feb. 2022).

Source: Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II, "The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison," To the Point (blog), Commonwealth Fund, Dec. 1, 2022. https://doi.org/10.26099/8vem-fc65

Care models and social supports

U.S. Maternal Mortality Rate Has Been Getting Worse over Time



Notes: The maternal mortality ratio is defined by the World Health Organization as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

Data: Data for all countries except US from <u>OECD Health Statistics 2022</u>. Data for US from Donna L. Hoyert, <u>Maternal Mortality Rates in the</u> <u>United States</u>, 2020 (National Center for Health Statistics, Feb. 2022).

Source: Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II, "The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison," To the Point (blog), Commonwealth Fund, Dec. 1, 2022. https://doi.org/10.26099/8vem-fc65

Exhibit 3

Maternal Care Workforce: Supply of Midwives and Ob-Gyns, 2018 or Latest Year



Download data

* The "sum" figure shown to the right of horizontal bars may not reflect arithmetic sum of figures shown for Ob-Gyn and midwife providers because calculations were performed on exact figures, while the figure presents rounded figures.

Data: OECD Health Data 2020, representing "practicing midwives" except: Canadian data reflect "professionally active" midwives; U.S. data reflect midwives "licensed to practice." Data for professionals "licensed to practice" tend to be higher than data for "professionally active," while numbers of "practicing" professionals tend to be the lowest. Data for 2018 except 2017 for Australia, Canada, Sweden, and 2015 for the U.S. Reflects midwifery professionals and midwifery associate professionals as defined by the International Standard Classification of Occupations (ISCO-08 codes 2222 and 3222, respectively). U.S. data reflect certified nursemidwives (CNM), certified midwives (CM), and certified professional midwives (CPM) by the AMCB, and the NARM, but excludes noncertified midwives (i.e., lay midwives). "Sum" does not reflect total maternity care workforce, since primary care physicians/family practitioners also deliver some care in many countries (not shown here).

Source: Roosa Tikkanen et al., Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries (Commonwealth Fund, Nov. 2020). https://doi.org/10.26099/411v-9255

Care models and social supports

U.S. Maternal Mortality Rate Has Been Getting Worse over Time

Deaths per 100,000 live births



Notes: The maternal mortality ratio is defined by the World Health Organization as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

Data: Data for all countries except US from <u>OECD Health Statistics 2022</u>. Data for US from Donna L. Hoyert, <u>Maternal Mortality Rates in the</u> <u>United States</u>, 2020 (National Center for Health Statistics, Feb. 2022).

Source: Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II, "The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison," To the Point (blog), Commonwealth Fund, Dec. 1, 2022. <u>https://doi.org/10.26099/8vem-fc65</u>

Exhibit 5 Weeks of Paid Maternity Leave, 2018



Data: OECD Family Database, 2018 data. Data reflect paid maternity, parental, and home care leave available to mothers.

Source: Roosa Tikkanen et al., Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries (Commonwealth Fund, Nov. 2020). https://doi.org/10.26099/411v-9255

Care models and social supports

U.S. Maternal Mortality Rate Has Been Getting Worse over Time



Notes: The maternal mortality ratio is defined by the World Health Organization as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

Data: Data for all countries except US from OECD Health Statistics 2022. Data for US from Donna L. Hoyert, <u>Maternal Mortality Rates in the</u> <u>United States, 2020</u> (National Center for Health Statistics, Feb. 2022).

Source: Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II, "The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison," To the Point (blog), Commonwealth Fund, Dec. 1, 2022. https://doi.org/10.26099/8vem-fc65

Exhibit 4 Postpartum Home Visits

	Covered by national insurance?	Timing and number of covered visits	Provider
Australia	Yes	Within week 1, typically one to three visits	Midwife
Canada	Yes	Contacted or visited within 24 to 48 hours after going home	Public health nurse
France	Yes	Starting within 24 hours after discharge, one to three visits	Midwife
Germany	Yes	Daily if needed until day 10, plus 16 visits as needed until eight weeks postpartum	Midwife
Netherlands	Yes	Daily, starting immediately after birth and up to 10 days postpartum, staying at a minimum 4 hours per day	Maternity nurse
New Zealand	Yes	At least five visits over six weeks, starting within 48 hours postpartum	Midwife
Norway	Ves	Midwife: Starting at 24 to 48 hours, or three days (for low-risk multiparous women) after going home	Midwife nurse
Normay	165	Nurse: First visit on days 7 to 10 postpartum; second visit on days 14 to 21	mame, nu se
Sweden	Yes	First visit during week 1; visits thereafter every one to two weeks until week 8	Midwife, nurse
Switzerland	Yes	Daily, up to 10 days postpartum	Midwife
United Kingdom	Yes	At least until 10 days postpartum	Midwife, nurse
United States	Covered by some state Medicaid programs and certain health plans	Varies by state Medicaid program and by individual insurer	Nurse, physician, community health worker, doula, home health worker



Contributors to postpartum HDP morbidity and mortality





Of those with postpartum preeclampsia, 33-69% are

normotensive antepartum.



















Let's (fight to) reimagine care.

UC San Diego: Fourth Trimester Program

A program dedicated to providing comprehensive postpartum care for birthing people and their newborns through integration and co-location of health services.





Innovations on the horizon







DIAGNOSTICS

- Imbalance in antiangiogenic/pro-angiog enic circulating factors
- Volume overload

THERAPEUTICS

- Immunologic therapy
- Diuretic agents

MANAGEMENT

- Digital health tools
- Extended care
- Improvements in social support

Diuretics for postpartum hypertension

medRχiv

THE PREPRINT SERVER FOR HEALTH SCIENCES

Original Research

OBSTETRICS

Lasix for the prevention of de novo postpartum hypertension: a randomized placebo-controlled trial (LAPP Trial)



alog.org

Ukachi N. Emeruwa, MD, MPH; Hooman Azad, MD; Samsiya Ona, MD; Shai Bejerano, MS; Sarah Alnafisee, MD; Jordan Emont, MD, MPH, ScM; Sharon Mathew, BA; Michelle Batlle, MA; Denice Arnold, MD; Erinma P. Ukoha, MD, MPH; Louise C. Laurent, MD, PhD; Marni Jacobs, PhD; Janice J. Aubey, MD, MPH; Russell S. Miller, MD; Cynthia Gyamfi-Bannerman, MD, MS

Effects of Immediate Postpartum Diuretic Treatment on Postpartum Blood Pressure among Individuals with Hypertensive Disorders of Pregnancy:A Systematic Review and Meta-Analysis

Susan K. Keen, Koura Sall,
 Agnes Koczo, Yisi Wang, Rebekah S. Miller,
 Matthew F. Muldoon,
 Alisse K. Hauspurg,
 Malamo E. Countouris
 https://doi.org/10.1101/2025.01.03.25319983

Exploring equity in the use of innovation

New moms face barriers to care. Digital engagement tools can help.

Transportation issues

Childcare challenges

Work obligations

Ensure patients have access to care with digital tools – right from home



Emerging digital health tools



...

Big Data Analytics

Ö

...

•

BIG DATA

VECTOR ILLUSTRATION



Novel Fourth Trimester Services: early and frequent opportunities for interaction Co-located Postpartum assessment and newborn check up

Contraception counseling and provision

Mental health services

Lactation counseling and support

Coordinated transition to Primary Care

Stages of life and health



Natural stress-test





Life after pregnancy



Risk reduction: Preventing HDP



Risk reduction: Preventing HDP



• Optimize pre-pregnancy health

Innovations on the horizon



Successful transitions of care.

Empowering our patients and ourselves

Core elements of quality hypertension care

UC San Diego Health

Whole system problem, Whole system approach



Medical assistants Accurate BP is vital Ask about symptoms during intake



Community health workers Vital link post-discharge Home visits BP checks Reinforce education Connect to health system





Health educators

Create clear materials Lead patient classes









"Education is the most powerful weapon which you can use to change the world."

~ Nelson Mandela





"When you know better, you do better."

~ Maya Angelou

Thank you. Questions?

uemeruwa@health.ucsd.edu

- 🛛 @MissUkachi
- F MissUkachiisDrUk / ukachi.emeruwa

in ukachi-emeruwa

Who is at risk?

Risk Level	Risk Factors
High (1 or more)	 History of preeclampsia in previous pregnancy Multifetal gestation (twins, triplets, etc.) Chronic hypertension (high blood pressure) Type 1 or 2 diabetes Renal disease (kidney disease) Autoimmune disease (lupus, antiphospholipid syndrome, etc.)
Moderate (2 or more)	 Nulliparity (never having given birth) Obesity (body mass index (BMI) >30) Family history of preeclampsia (mother or sister) Age ≥35 or <18 years old Personal history (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-year pregnancy interval) Social Drivers of Health (e.g., Black, rural, Medicaid)
Low	Previous uncomplicated full-term delivery



 Pregnancy is marked by profound physiologic adaptations to accommodate (and secondary to) the growing feto-placental unit

Final Recommendation Statement: Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: Preventative Medicine. 2016. Retrieved from U.S. Preventive Services Task Force. Gestational hypertension and preeclampsia.

Who is at risk?

Risk Level	Risk Factors	
High (1 or more)	 History of preeclampsia in previous pregnancy Multifetal gestation (twins, triplets, etc.) Chronic hypertension (high blood pressure) Type 1 or 2 diabetes Renal disease (kidney disease) Autoimmune disease (lupus, antiphospholipid syndrome, etc.) 	
Moderate (2 or more)	 syndrome, etc.) Nulliparity (never having given birth) Obesity (body mass index (BMI) >30) Family history of preeclampsia (mother or sister) Age ≥35 or <18 years old Personal history (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-year pregnancy interval) Social Drivers of Health (e.g., Black, rural, Medicaid) 	
Low	 Previous uncomplicated full-term delivery 	



 Pregnancy is marked by profound physiologic adaptations to accommodate (and secondary to) the growing feto-placental unit

Final Recommendation Statement: Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: Preventative Medicine. 2016. Retrieved from U.S. Preventive Services Task Force. Gestational hypertension and preeclampsia.

Who is at risk?

Risk Level	Risk Factors	
High (1 or more)	 History of preeclampsia in previous pregnancy Multifetal gestation (twins, triplets, etc.) Chronic hypertension (high blood pressure) Type 1 or 2 diabetes Renal disease (kidney disease) Autoimmune disease (lupus, antiphospholipid syndrome, etc.) 	
Moderate (2 or more)	 syndrome, etc.) Nulliparity (never having given birth) Obesity (body mass index (BMI) >30) Family history of preeclampsia (mother or sister) Age ≥35 or <18 years old Personal history (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-year pregnancy interval) Social Drivers of Health (e.g., Black, rural, Medicaid) 	
Low	Previous uncomplicated full-term delivery	

Normal Pregnancy Blood Pressure



3

• Pregnancy is marked by profound physiologic adaptations to accommodate (and secondary to) the growing feto-placental unit

Final Recommendation Statement: Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: Preventative Medicine. 2016. Retrieved from U.S. Preventive Services Task Force. Gestational hypertension and preeclampsia.

Who is at risk?

Risk Level	Risk Factors	
High (1 or more)	 History of preeclampsia in previous pregnancy Multifetal gestation (twins, triplets, etc.) Chronic hypertension (high blood pressure) Type 1 or 2 diabetes Renal disease (kidney disease) Autoimmune disease (lupus, antiphospholipid syndrome, etc.) 	
Moderate (2 or more)	 syndrome, etc.) Nulliparity (never having given birth) Obesity (body mass index (BMI) >30) Family history of preeclampsia (mother or sister) Age ≥35 or <18 years old Personal history (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-year pregnancy interval) Social Drivers of Health (e.g., Black, rural, Medicaid) 	
Low	 Previous uncomplicated full-term delivery 	



 Derangements, deviations, or inability to accommodate these adaptations lead to pregnancy-associated pathology

Final Recommendation Statement: Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: Preventative Medicine. 2016. Retrieved from U.S. Preventive Services Task Force. Gestational hypertension and preeclampsia.

Who is at risk?

Risk Level	Risk Factors	
High (1 or more)	 History of preeclampsia in previous pregnancy Multifetal gestation (twins, triplets, etc.) Chronic hypertension (high blood pressure) Type 1 or 2 diabetes Renal disease (kidney disease) Autoimmune disease (lupus, antiphospholipid syndrome, etc.) 	
Moderate (2 or more)	 syndrome, etc.) Nulliparity (never having given birth) Obesity (body mass index (BMI) >30) Family history of preeclampsia (mother or sister) Age ≥35 or <18 years old Personal history (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-year pregnancy interval) Social Drivers of Health (e.g., Black, rural, Medicaid) 	
Low	 Previous uncomplicated full-term delivery 	

- Proven predisposition
- More placenta
- Baseline compromise in systems:
 - Vascular
 - Renal
 - Inflammatory
- "Guilty until proven innocent"
- Baseline physiologic stress
- ?Genetic predisposition
- Immature or compromised adaptive potential
- Predisposition to other placental dysfunction
- Contributors to physiologic stress

Final Recommendation Statement: Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: Preventative Medicine. 2016. Retrieved from U.S. Preventive Services Task Force. Gestational hypertension and preeclampsia.